Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

NCT03722407 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Leukemia

Interventions

DRUG: Ruxolitinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]